Clinical Trial: Clinical Benefits of the Closed Loop Stimulation in Sinus Node Disease

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Clinical Benefits of the Closed Loop Stimulation in Sinus Node Disease - B3 Study

Brief Summary: The study is designed as a multi-center, international, prospective, parallel, randomized, single blinded trial comparing the time to first primary endpoint event (Sustained Paroxysmal AF/Persistent AF or stroke/TIA) occurrence in a follow up period of 3 years, between Closed Loop Stimulation (CLS) ON versus OFF, on top of a DDD pacing in patients with pacemaker or ICD indication who require dual-chamber pacing due to sinus node disease (SND), with or without atrioventricular (AV) block.

Detailed Summary:

The benefits of rate-responsiveness on top of dual-chamber pacing still need to be definitively assessed in Sinus Node Dysfunction (SND). Although many rate responsive (RR) sensors have been developed, no large clinical trials evaluated their benefits in terms of clinical endpoints such as clinically relevant atrial fibrillation (AF) and stroke. Electromechanical sensors (piezoelectric accelerometers) have been widely used for their simplicity and overall reliability. However there is some evidence indicating the Closed Loop Stimulation as one of the more efficient and physiological sensors.

Two randomized clinical studies have been conducted so far, showing that in the Brady-Tachy Syndrome the CLS algorithm was associated with a significantly lower overall atrial arrhythmia burden as compared both with a DDDR mode based on a standard accelerometric sensor and an atrial overdrive approach.

Both studies yielded consistent results, albeit with a parallel and intraindividual comparison designs, respectively. The atrial arrhythmic burden is an important but surrogate endpoint, not necessarily related to long-term clinical outcome. The CLS effects on AF (if any) should be investigated in terms of time to first new onset of clinically relevant AF.

In the light of these considerations, it appears interesting to run a large randomized study coherently collecting data on the overall clinical benefit of CLS, primarily in terms of AF and stroke, in a population indicated for pacemaker or ICD and needing dual-chamber pacing due to SND.


Sponsor: Biotronik SE & Co. KG

Current Primary Outcome: First event of Sustained Paroxysmal AF or Persistent AF or stroke or TIA, whichever comes first. [ Time Frame: three years ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Sustained Paroxysmal AF (SPAF) [ Time Frame: Three years ]
    Assess the date of each events of SPAF occurred during the follow-up periods
  • Persistent AF [ Time Frame: Three years ]
    Assess the date of each events of peristent AF occurred during the follow-up periods
  • Permanent AF [ Time Frame: Three years ]
    Assess the date when AF is declared permanent
  • Stroke/TIA [ Time Frame: Three years ]
    Assess the date of each events of stroke/TIA occurred during the follow-up periods
  • Worsening Heart failure Hospitalization (wHF-H) [ Time Frame: Three years ]
    Assess the date of each events of wHF-H occurred during the follow-up periods
  • All cause mortality [ Time Frame: Three years ]


Original Secondary Outcome: Same as current

Information By: Biotronik SE & Co. KG

Dates:
Date Received: October 16, 2015
Date Started: September 2015
Date Completion: January 2021
Last Updated: March 8, 2017
Last Verified: March 2017